E-LIB Suche - Ergebnisse für: Ascierto PA

1

Late onset Blueberry Muffin Syndrome following congenital r..:

Vozza, A ; Tolone, C ; Carrano, Em...
Journal of the European Academy of Dermatology and Venereology. 17 (2003) 2 - p. 204-205 , 2003

Link: https://doi.org/10.1046/..

2

Sentinel Lymph Node Biopsy to Stage Patients with Cutaneous..:

Caracò, C ; Chiofalo, MG ; Niro, J...
Tumori Journal. 88 (2002) 3 - p. S12-S13 , 2002

Link: https://doi.org/10.1177/..

3

A tailored approach to horizon scanning for cancer medicine:

Soon, JA ; To, YH ; Alexander, M...
ARTN 100441. , 2024

Link: https://repository.icr.a..

4

First-line, Fixed-Duration Nivolumab plus Ipilimumab Follow..:

1. Dummer R ; Corrie P ; Gutzmer R...
info:eu-repo/semantics/altIdentifier/pmid/37307514. , 2023

Link: https://hdl.handle.net/1..

5

Potential clinical implications of CD4+CD26high T cells for..:

Galati D ; Zanotta S ; Capone M...
volume:21. , 2023

Link: https://hdl.handle.net/1..

6

Neoadjuvant plus adjuvant combined or sequenced vemurafenib..:

Ascierto PA ; Cioli E ; Chiarion-Sileni V...
info:eu-repo/semantics/altIdentifier/pmid/36845751. , 2023

Link: https://hdl.handle.net/1..

7

Type 2 diabetes mellitus and efficacy outcomes from imune c..:

Cortellini A ; D'Alessio A ; Cleary S...
info:eu-repo/semantics/altIdentifier/wos/WOS:001043737000001. , 2023

Link: https://hdl.handle.net/1..

8

Characteristics of Real-World Patients with High-Risk BRAFV..:

Quaglino P ; Ascierto PA ; Consoli F...
https://www.dovepress.com/characteristics-of-real-world-patients-with-high-risk-brafv600ek-mutat-peer-reviewed-fulltext-article-CMAR. , 2023

Link: https://doaj.org/article..

9

Nivolumab and Relatlimab in Patients With Advanced Melanoma..:

Ascierto, PA ; Lipson, EJ ; Dummer, R...
Journal of Clinical Oncology, 2023, pp. JCO2202072 -. , 2023

Link: https://repository.icr.a..

10

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Mela..:

Diab, A ; Gogas, H ; Sandhu, S...
Journal of Clinical Oncology, 2023, 41 (30), pp. 4756 - 4767. , 2023

Link: https://repository.icr.a..

11

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as ..:

Bai, X ; Shaheen, A ; Grieco, C...
102290. , 2023

Link: https://repository.icr.a..

12

Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/..:

Larkin, J ; Del Vecchio, M ; Mandala, M...
725906. , 2023

Link: https://repository.icr.a..

13

Prognostic and predictive value of beta-blockers in the EOR..:

Kennedy, OJ ; Kicinski, M ; Valpione, S...
issn:0959-8049. , 2022

Link: http://hdl.handle.net/11..

14

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolu..:

Wolchok, JD ; Chiarion-Sileni, V ; Gonzalez, R...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 40 (2), pp. 127 - 137. , 2022

Link: https://repository.icr.a..

15

Health-related quality of life impact of cobimetinib in com..:

Dréno, B ; Ascierto, PA ; Atkinson, V...
bjc2017488. , 2022

Link: https://repository.icr.a..